CClinicalTrials.gg
RecruitingNCT07209436Updated Jan 22, 2026

Impact of Pectoral Versus Paravertebral Blocks on Pain and Physical Well-Being in Implant-Based Breast Reconstruction

An interventional study of Paravertebral block (single injection) and Pectoral block in Breast Reconstruction, sponsored by Amy Colwell. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-22.

Sponsored by Amy Colwell · Not applicable, Interventional, and Supportive care

From the registry’s dates

  • Started Nov 2025; still recruiting 10 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
212
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The broad aim of this study is to compare the effectiveness of paravertebral and pectoral blocks on pain and physical well-being of patients undergoing immediate implant-based breast reconstruction.

02

Conditions studied

  • Breast Reconstruction

Browse trials for

Keywords

  • Breast Reconstruction
  • Breast cancer
03

In context

Breast Neoplasms

12,544 studies on the registry are indexed under Breast Neoplasms; 2,892 are open to participants now.

This study's planned enrollment of 212 is above the median of 72 across 9,303 interventional studies indexed under Breast Neoplasms.

Browse Breast Neoplasms studies →

Lead sponsor

This is the only study on the registry with Amy Colwell as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Adult patient 18 years or older
  • Scheduled for unilateral or bilateral immediate implant-based breast reconstruction
  • Therapeutic or prophylactic indication
  • Patient understands the study procedures and objectives and is willing to participate
  • Patient willing to and capable of providing informed consent

Exclusion criteria

Exclusion Criteria:

  • Delayed breast reconstruction
  • Allergy or contraindication to local anesthetics (PVB or PECS blocks)
  • History of radiation therapy
  • Planned sedation or general anesthesia protocol variation
  • Morbid obesity as defined as a BMI greater than 40 kg/m2
  • Renal insufficiency
  • Chronic pain syndrome or central sensitization disorders (e.g., fibromyalgia, CRPS)
  • Use of implanted pain devices or neuromodulators
  • Pre-existing neurological deficits in the surgical field
  • Current chronic opioid use (daily use within the 2 weeks before surgery and duration of use greater than 4 weeks)
  • Use of any nerve medications in the past 6 months, including antiepileptic medications (gabapentin, carbamazepine)
  • History of drug or alcohol abuse or habitual alcohol intake greater than two standard drinks per day (e.g., two beers, two glasses of wine, or two mixed drinks)
  • Any comorbidity that results in moderate or severe functional limitation, inability to communicate with the investigators or hospital staff
  • History of a psychiatric disorder which would interfere with the study procedure
  • Incarceration
  • Any issue that at the discretion of the investigator would contraindicate the subject's participation
  • Inability to understand the procedures and objectives of the study
  • Inability to or unwilling to provide informed consent
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
212 participants (estimated)

Study arms

  • Active comparator
    Paravertebral Block

    Paravertebral block at preop

    Procedure: Paravertebral block (single injection)

  • Experimental
    Pectoral Block

    Pectoral block at preop

    Procedure: Pectoral block

Interventions

  • ProcedureParavertebral block (single injection)

    Paravertebral block at preop

  • ProcedurePectoral block

    Pectoral block at preop

06

What researchers measure

Primary outcomes

  1. Patient-reported physical well-being and breast symptoms

    Patient-reported physical well-being and breast symptoms will be evaluated using the Breast Quality of Life Physical Well-Being and Breast Symptoms scales. Values are scores from 0 to 100, with higher scores indicating better satisfaction or quality of life for patients undergoing breast surgery, such as those with breast cancer. These scores are derived from patient-reported outcome measures across different domains like satisfaction with breasts, psychosocial well-being, physical well-being (chest and abdomen), and sexual well-being.

    Time frame: 12 Months

  2. Brief Pain Inventory (BPI) Scoring

    The BPI is a self-report questionnaire that assesses pain intensity and interference. It consists of two parts: Pain Severity: Measures the intensity of pain using a 0-10 scale, where 0 is "no pain" and 10 is "worst possible pain." Pain Interference: Measures how much pain interferes with daily activities using a 0-10 scale for seven items (e.g., general activity, mood, sleep). Calculation of Scores: Pain Severity Score: Add up the scores for the four pain severity questions (worst pain, least pain, average pain, current pain) and divide by 4. Pain Interference Score: Add up the scores for the seven pain interference questions and divide by 7. Interpretation: Pain Severity: 0-3: Mild pain 4-6: Moderate pain 7-10: Severe pain Pain Interference: Higher scores indicate greater interference with daily activities.

    Time frame: 12 Months

07

Study locations

1 of 1 sites recruiting
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07209436
Lead sponsor
Amy Colwell
Responsible party
Amy Colwell (Sponsor-Investigator, Massachusetts General Hospital) — Sponsor-investigator
First posted
Oct 7, 2025
Start date
Nov 19, 2025
Primary completion
Jun 30, 2027 (estimated)
Completion
Jun 2028 (estimated)
Last update
Jan 22, 2026

Study contacts

Cathleen Huang, D.O.
Contact
CHUANG24@DFCI.HARVARD.EDU
617-726-2284
Amy Colwell, M.D.
principal investigator · Massachusetts General Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion